Naoto Takahashi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5629997/publications.pdf

Version: 2024-02-01

125 papers	2,499 citations	218381 26 h-index	233125 45 g-index
130 all docs	130 docs citations	130 times ranked	2864 citing authors

#	Article	IF	Citations
1	Lineage Involvement of Stem Cells Bearing the Philadelphia Chromosome in Chronic Myeloid Leukemia in the Chronic Phase as Shown by a Combination of Fluorescence-Activated Cell Sorting and Fluorescence In Situ Hybridization. Blood, 1998, 92, 4758-4763.	0.6	161
2	A Clinical Analysis of 52 Adult Patients With Hemophagocytic Syndrome: The Prognostic Significance of the Underlying Diseases. International Journal of Hematology, 2001, 74, 209-213.	0.7	153
3	Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. Journal of Human Genetics, 2010, 55, 731-737.	1.1	147
4	Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica, 2012, 97, 903-906.	1.7	138
5	Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase. Annals of Internal Medicine, 2018, 168, 461.	2.0	105
6	A Clinicopathological Study of 20 Patients With T/Natural Killer (NK)-Cell Lymphoma-Associated Hemophagocytic Syndrome With Special Reference to Nasal and Nasal-Type NK/T-Cell Lymphoma. International Journal of Hematology, 2001, 74, 303-308.	0.7	93
7	Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. International Journal of Hematology, 2018, 107, 185-193.	0.7	72
8	Fluorescence In Situ Hybridization of Progenitor Cells Obtained by Fluorescence-Activated Cell Sorting for the Detection of Cells Affected by Chromosome Abnormality Trisomy 8 in Patients With Myelodysplastic Syndromes. Blood, 1998, 92, 2886-2892.	0.6	67
9	Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica, 2018, 103, 1835-1842.	1.7	59
10	Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. Journal of Experimental Medicine, 2020, 217, .	4.2	58
11	A synthetic double-stranded RNA, poly I:C, induces a rapid apoptosis of human CD34+ cells. Experimental Hematology, 2012, 40, 330-341.	0.2	52
12	Hypoxia-inducible KDM3A addiction in multiple myeloma. Blood Advances, 2018, 2, 323-334.	2.5	50
13	An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. Blood, 2020, 135, 2337-2353.	0.6	49
14	Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemotherapy and Pharmacology, 2012, 69, 999-1004.	1.1	43
15	Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLCâ€“UV or LCâ€“MS/MS methods. Drug Metabolism and Pharmacokinetics, 2016, 31, 12-20.	1.1	41
16	Molecular heterogeneity of the NUP98/HOXA9 fusion transcript in myelodysplastic syndromes associated with t(7;11)(p15;p15). British Journal of Haematology, 1999, 107, 600-604.	1.2	40
17	Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nature Communications, 2021, 12, 2833.	5.8	39
18	Quantitative Determination of Imatinib in Human Plasma with High-Performance Liquid Chromatography and Ultraviolet Detection. Journal of Chromatographic Science, 2011, 49, 412-415.	0.7	37

#	Article	IF	Citations
19	Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients in the Chronic Phase. Pharmacology, 2011, 87, 241-248.	0.9	36
20	Influence of UGT1A1 *6, *27, and *28 Polymorphisms on Nilotinib-induced Hyperbilirubinemia in Japanese Patients with Chronic Myeloid Leukemia. Drug Metabolism and Pharmacokinetics, 2014, 29, 449-454.	1.1	35
21	Hypoxiaâ€inducible hexokinaseâ€2 enhances antiâ€apoptotic function via activating autophagy in multiple myeloma. Cancer Science, 2020, 111, 4088-4101.	1.7	34
22	Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study. International Journal of Hematology, 2017, 106, 385-397.	0.7	33
23	Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence-activated cell sorting. British Journal of Haematology, 2000, 110, 876-879.	1.2	32
24	Hypoxiaâ€inducible micro<scp>RNA</scp>â€210 regulates the <scp>DIMT</scp>1â€<scp>IRF</scp>4 oncogenic axis in multiple myeloma. Cancer Science, 2017, 108, 641-652.	1.7	31
25	Highâ€performance liquid chromatography with solidâ€phase extraction for the quantitative determination of nilotinib in human plasma. Biomedical Chromatography, 2010, 24, 789-793.	0.8	30
26	Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants. European Journal of Clinical Pharmacology, 2013, 69, 1321-1329.	0.8	30
27	A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction. Haematologica, 2013, 98, 1407-1413.	1.7	29
28	Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. International Journal of Hematology, 2019, 109, 426-439.	0.7	29
29	Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma. Oncotarget, 2017, 8, 7572-7585.	0.8	27
30	Drug interaction between lenalidomide and itraconazole. American Journal of Hematology, 2012, 87, 338-339.	2.0	25
31	Itraconazole Oral Solution Enhanced Vincristine Neurotoxicity in Five Patients with Malignant Lymphoma. Internal Medicine, 2008, 47, 651-653.	0.3	24
32	Kidney-limited intravascular large B cell lymphoma: a distinct variant of IVLBCL?. International Journal of Hematology, 2009, 89, 533-537.	0.7	24
33	Erythroblast enucleation is a dynein-dependent process. Experimental Hematology, 2016, 44, 247-256.e12.	0.2	24
34	A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. International Journal of Hematology, 2015, 101, 154-164.	0.7	23
35	Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients. Leukemia Research, 2018, 64, 42-45.	0.4	23
36	Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation. Journal of Hematology and Oncology, 2012, 5, 23.	6.9	21

#	Article	IF	Citations
37	Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia. Experimental Hematology and Oncology, 2018, 7, 9.	2.0	21
38	JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN). International Journal of Hematology, 2020, 112, 268-291.	0.7	21
39	Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma. Oncotarget, 2016, 7, 13563-13574.	0.8	21
40	Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib. Biomarker Research, 2014, 2, 6.	2.8	20
41	Rearrangements of the BCL6 Gene and Chromosome Aberrations Affecting 3q27 in 54 Patients with Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1997, 27, 329-334.	0.6	18
42	Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. Leukemia, 2021, 35, 1631-1642.	3.3	18
43	ATP produced by anaerobic glycolysis is essential for enucleation of human erythroblasts. Experimental Hematology, 2019, 72, 14-26.e1.	0.2	17
44	Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study. International Journal of Hematology, 2008, 87, 195-202.	0.7	16
45	The localization of Î±-synuclein in the process of differentiation of human erythroid cells. International Journal of Hematology, 2018, 108, 130-138.	0.7	16
46	Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop. Blood, 2016, 128, 792-792.	0.6	16
47	BCR-ABL Activates IGF-1 Expression and Signaling in Chronic Myelogenous Leukemia Blast Crisis Cell Lines.. Blood, 2006, 108, 1932-1932.	0.6	16
48	Molecular features of a new human lymphoma cell line carrying both BCL2 and BCL6 gene rearrangements. Oncogene, 1998, 17, 971-979.	2.6	15
49	11q23 Aberration is an additional chromosomal change in de novo acute leukemia after treatment with etoposide and mitoxantrone. , 1996, 53, 264-266.		14
50	Fluorescence In Situ Hybridization Monitoring of BCR-ABL-Positive Neutrophils in Chronic-Phase Chronic Myeloid Leukemia Patients during the Primary Stage of Imatinib Mesylate Therapy. International Journal of Hematology, 2005, 81, 235-241.	0.7	14
51	Drug interaction of (S)-warfarin, and not (R)-warfarin, with itraconazole in a hematopoietic stem cell transplant recipient. Clinica Chimica Acta, 2011, 412, 2002-2006.	0.5	14
52	IL-6 Generated from Human Hematopoietic Stem and Progenitor Cells through TLR4 Signaling Promotes Emergency Granulopoiesis by Regulating Transcription Factor Expression. Journal of Immunology, 2021, 207, 1078-1086.	0.4	14
53	Fatal hemorrhagic pneumonia caused by Stenotrophomanas maltophilia in a patient with non-Hodgkin lymphoma. Journal of Infection and Chemotherapy, 2011, 17, 858-862.	0.8	13
54	Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor. Cancer Science, 2020, 111, 3714-3725.	1.7	13

#	Article	IF	Citations
55	Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation. Cancer Chemotherapy and Pharmacology, 2016, 78, 111-118.	1.1	12
56	Acute Myelogenous Leukemia Associated with a Mediastinal Tumor. Leukemia and Lymphoma, 1993, 12, 143-146.	0.6	11
57	Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure. American Journal of Hematology, 2012, 87, 451-451.	2.0	11
58	Cdc42 regulates cell polarization and contractile actomyosin rings during terminal differentiation of human erythroblasts. Scientific Reports, 2020, 10, 11806.	1.6	11
59	Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212. Blood, 2020, 136, 40-41.	0.6	11
60	Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia. International Journal of Hematology, 2020, 112, 24-32.	0.7	10
61	Lineage Involvement of Stem Cells Bearing the Philadelphia Chromosome in Chronic Myeloid Leukemia in the Chronic Phase as Shown by a Combination of Fluorescence-Activated Cell Sorting and Fluorescence In Situ Hybridization. Blood, 1998, 92, 4758-4763.	0.6	10
62	Effect of oral itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3. American Journal of Hematology, 2010, 85, 634-635.	2.0	9
63	H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology, 2012, 70, 351-352.	1.1	9
64	Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide. Therapeutic Drug Monitoring, 2018, 40, 301-309.	1.0	9
65	Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma. International Journal of Hematology, 2018, 108, 510-515.	0.7	9
66	High-throughput sequencing of IgG B-cell receptors reveals frequent usage of the rearranged IGHV4â€“28/IGHJ4 gene in primary immune thrombocytopenia. Scientific Reports, 2019, 9, 8645.	1.6	9
67	Hypereosinophilic syndrome with abundant Charcot-Leyden crystals in spleen and lymph nodes. Asia Pacific Allergy, 2020, 10, e24.	0.6	9
68	Multiple myeloma with t(11;14)â€assocIated immature phenotype has lower CD38 expression and higher BCL2 dependence. Cancer Science, 2021, 112, 3645-3654.	1.7	8
69	Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease. European Journal of Clinical Pharmacology, 2015, 71, 1091-1097.	0.8	7
70	Multiple Myelomaâ€“Associated Ig Light Chain Crystalline Cast Nephropathy. Kidney International Reports, 2020, 5, 1595-1602.	0.4	7
71	The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration. International Journal of Hematology, 2021, 113, 100-105.	0.7	7
72	Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia. International Journal of Clinical Oncology, 2013, 18, 983-987.	1.0	6

#	Article	IF	Citations
73	Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment. International Journal of Hematology, 2017, 106, 398-410.	0.7	6
74	Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia. Medical Oncology, 2018, 35, 90.	1.2	6
75	Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma. Medical Oncology, 2019, 36, 55.	1.2	6
76	Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study.. Journal of Clinical Oncology, 2016, 34, 7054-7054.	0.8	6
77	ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).. Journal of Clinical Oncology, 2019, 37, 7005-7005.	0.8	6
78	Comparative proteomic analysis of renal proteins from IgA nephropathy model mice and control mice. Clinical and Experimental Nephrology, 2020, 24, 666-679.	0.7	6
79	Downregulation of miRâ€26 promotes invasion and metastasis via targeting interleukinâ€22 in cutaneous Tâ€cell lymphoma. Cancer Science, 2022, 113, 1208-1219.	1.7	6
80	Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis. International Journal of Hematology, 2022, 115, 838-851.	0.7	6
81	A Limited Sampling Model to Estimate Exposure to Lenalidomide in Multiple Myeloma Patients. Therapeutic Drug Monitoring, 2014, 36, 505-509.	1.0	5
82	TAFRO Syndrome with Bilateral Adrenal Hemorrhage. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 288-294.	0.0	5
83	The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma. Annals of Hematology, 2018, 97, 1097-1099.	0.8	4
84	Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line. International Journal of Hematology, 2020, 111, 812-825.	0.7	4
85	Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy. Scientific Reports, 2021, 11, 6362.	1.6	4
86	Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.. Journal of Clinical Oncology, 2018, 36, 7003-7003.	0.8	4
87	Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia. Blood, 2021, 138, 4457-4457.	0.6	4
88	Phagocytosis of co-developing neutrophil progenitors by dendritic cells in a culture of human CD34+ cells with granulocyte colony-stimulating factor and tumor necrosis factor-Î±. International Journal of Hematology, 2008, 88, 64-72.	0.7	3
89	Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan. International Journal of Hematology, 2018, 108, 176-183.	0.7	3
90	Effects of proprotein convertase subtilisin/kexin type 9 and nilotinib plasma concentrations on nilotinibâ€induced hypercholesterolaemia in patients with chronic myeloid leukaemia. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 382-387.	0.7	3

#	Article	IF	Citations
91	The Genomic and Epigenomic Landscapes of Blast Crisis Transformation in Chronic Myeloid Leukemia. Blood, 2015, 126, 3737-3737.	0.6	3
92	Fluorescence In Situ Hybridization of Progenitor Cells Obtained by Fluorescence-Activated Cell Sorting for the Detection of Cells Affected by Chromosome Abnormality Trisomy 8 in Patients With Myelodysplastic Syndromes. Blood, 1998, 92, 2886-2892.	0.6	3
93	Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. Cancers, 2021, 13, 5904.	1.7	3
94	Bile acid is important for gastrointestinal absorption of nilotinib. European Journal of Clinical Pharmacology, 2012, 68, 1575-1576.	0.8	2
95	Effect of low platelet HLA-C expression on donor-specific antibody depletion following platelet transfusion from a corresponding HLA donor. Bone Marrow Transplantation, 2019, 54, 1713-1716.	1.3	2
96	Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 219-222.	0.7	2
97	The Combination of Interferon-Alpha and Ponatinib Enables Faster and Deeper Molecular Responses in Patient with De Novo Blast Crisis of CML: Interferon-Alpha May Return as a CML Treatment. Case Reports in Hematology, 2021, 2021, 1-4.	0.3	2
98	Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Phâ€‰+â€‰ALL. International Journal of Hematology, 2021, 114, 509-516.	0.7	2
99	Dasatinib Cerebrospinal Fluid Concentration and Plasma Pharmacokinetics: Potential for Central Nervous System Prophylaxis In Philadelphia Chromosome-Positive Leukemia. Blood, 2010, 116, 1807-1807.	0.6	2
100	A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2012, 30, 8023-8023.	0.8	2
101	Safety, Feasibility and Efficacy of High Dose Ranimustine (MCNU), Carboplatin, Etoposide, and Cyclophosphamide (MCVC) Therapy Followed by Autologous Stem Cell Transplantation for Malignant Lymphoma.. Blood, 2010, 116, 4588-4588.	0.6	2
102	Interim Analysis of Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study of Patients with AML. Blood, 2020, 136, 2-3.	0.6	2
103	Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy. Cancer Chemotherapy and Pharmacology, 2022, 89, 609-616.	1.1	2
104	Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis. Annals of Hematology, 2016, 95, 2087-2088.	0.8	1
105	Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant. Clinical Case Reports (discontinued), 2017, 5, 605-607.	0.2	1
106	Thrombocytopenia Caused by a Tea Beverage of Taxus yunnanensis (Chinese Yew). Internal Medicine, 2019, 58, 3153-3156.	0.3	1
107	RIZ1 Is Downregulated during CML Progression and Displays Tumor Suppressor Properties in CML Cell Lines.. Blood, 2006, 108, 2134-2134.	0.6	1
108	Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01. Blood, 2021, 138, 2313-2313.	0.6	1

#	Article	IF	Citations
109	Early prediction of a long-term outcome by neutrophil-FISH in patients with CML receiving imatinib mesylate. International Journal of Hematology, 2010, 92, 559-561.	0.7	0
110	Hypereosinophilic Syndrome in the Tyrosine Kinase Inhibitor Era. Internal Medicine, 2015, 54, 551-552.	0.3	0
111	Clinical Analysis of Adult Acute Leukemia with Rearrangements of the 11q23/MLL: Multicenter Co-Operative Study.. Blood, 2006, 108, 2354-2354.	0.6	0
112	Phagocytosis of Co-Developing Neutrophil Progenitors by Dendritic Cells in Culture with Granulocyte-Colony Stimulating-Factor and Tumor Necrosis Factor-Î±: Induction of T Regulatory Cells by Co-Developing Dendritic Cells.. Blood, 2006, 108, 1720-1720.	0.6	0
113	Low Level of Serum Haptoglobin in Patients with Acquired Bone Marrow Failure (BMF) Syndromes.. Blood, 2007, 110, 3774-3774.	0.6	0
114	Low Dose and Standard Dose of Imatinib Therapy for Patients with Chronic Myeloid Leukemia in Akita Prefecture, Japan.. Blood, 2007, 110, 4575-4575.	0.6	0
115	Personalized Therapy of Tyrosine Kinase Inhibitors. Japanese Journal of Clinical Pharmacology and Therapeutics, 2013, 44, 225-228.	0.1	0
116	Effective Steroid Pulse Therapy for mitigate the acute phase symptoms of Human herpesvirus 6 encephalitis after allogenic hematopoietic stem cell transplantation: experience of two cases. Journal of Hematopoietic Cell Transplantation, 2013, 2, 75-79.	0.1	0
117	Ponatinib Safety and Efficacy in Japanese Patients with Philadelphia Positive Leukemia: Update of a Phase 1/2 Study. Blood, 2014, 124, 5541-5541.	0.6	0
118	Functional Analysis of the CML Blast Crisis Transcriptome and Epigenome Using Crispr-CAS9 and Pharmacologic Approaches. Blood, 2015, 126, 2764-2764.	0.6	0
119	7. Diagnosis and Treatment of Chronic Myeloid Leukemia and Myeloproliferative Neoplasms. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 547-550.	0.0	0
120	Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis. Blood, 2021, 138, 4447-4447.	0.6	0
121	Efficacy and Safety of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study. Blood, 2021, 138, 2557-2557.	0.6	0
122	Genomic Analysis of NPM1 Mutation and KMT2A(MLL)-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01. Blood, 2021, 138, 4460-4460.	0.6	0
123	Patient and Physician Perspectives of Unmet Needs in CML - Designing the CML SUN Survey. Blood, 2021, 138, 4986-4986.	0.6	0
124	Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01. Blood, 2020, 136, 35-36.	0.6	0
125	Genomic Analysis of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01. Blood, 2020, 136, 32-34.	0.6	0